{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:30:02Z","timestamp":1750480202423},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,4,15]]},"DOI":"10.2169\/internalmedicine.5089-20","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T22:09:13Z","timestamp":1605478153000},"page":"1183-1190","source":"Crossref","is-referenced-by-count":6,"title":["A Multicenter Study of Docetaxel at a Dose of 100 mg\/m&lt;sup&gt;2&lt;\/sup&gt; in Japanese Patients with Advanced or Recurrent Breast Cancer"],"prefix":"10.2169","volume":"60","author":[{"given":"Taizo","family":"Hirata","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tabata","sequence":"additional","affiliation":[{"name":"Departments of Allergy and Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Hinotsu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Sapporo Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Motoki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Okayama Saiseikai General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tsuyama Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[{"name":"Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[{"name":"Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Doihara","sequence":"additional","affiliation":[{"name":"Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963-4970, 2006.","DOI":"10.1200\/JCO.2005.05.0294"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999.","DOI":"10.1200\/JCO.1999.17.5.1413"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542-5551, 2005.","DOI":"10.1200\/JCO.2005.02.027"},{"key":"4","unstructured":"4. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced\/recurrent breast cancer. Gan To Kagaku Ryoho 21: 2625-2632, 1994 (in Japanese, Abstract in English)."},{"key":"5","unstructured":"5. Nakamura S, Masuda S, Iwata H, et al. Phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC) Followed by docetaxel 100 mg\/m<sup>2<\/sup> in primary operable breast cancer -JBCRG02-. Jpn J Breast Cancer 23: 111-117, 2008 (in Japanese, Abstract in English)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shou M, Hayashi M, Pan Y, et al. Modeling, prediction, and <i>in vitro in vivo<\/i> correlation of CYP3A4 induction. Drug Metab Dispos 36: 2355-2370, 2008.","DOI":"10.1124\/dmd.108.020602"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Roberts PJ, Rollins KD, Kashuba AD, et al. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 36: 1465-1469, 2008.","DOI":"10.1124\/dmd.107.020065"},{"key":"8","unstructured":"8. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47: 8-32, 2011."},{"key":"9","unstructured":"9. National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology (NCCN Guidelines<sup>\u00ae<\/sup>). Myelooid growth factors. Version 2. 2014 [Internet]. [cited 2016 Aug 31]. Available from: http:\/\/williams.medicine.wisc.edu\/myeloid_growth.pdf"},{"key":"10","unstructured":"10. Yano R, Konno A, Watanabe K, et al. Pharmacoethnicity of docetaxelinduced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol 18: 96-104, 2013."},{"key":"11","unstructured":"11. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23: 1178-1184, 2005."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kosaka Y, Rai Y, Masuda N, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23: 1137-1143, 2015.","DOI":"10.1007\/s00520-014-2597-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91 (Suppl 2): S3-S10, 2004.","DOI":"10.1038\/sj.bjc.6602061"},{"key":"14","unstructured":"14. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced nonsmall- cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24: 3657-3663, 2006."},{"key":"15","unstructured":"15. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Japan Med Assoc J 50: 405-411, 2006."},{"key":"16","unstructured":"16. Koo L, Clark J, Quesenberry CP, et al. National differences in reporting &quot;pneumonia&quot; and &quot;pneumonia interstitial&quot;: an analysis of the WHO drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 14: 775-787, 2005."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: 3426-3432, 1998.","DOI":"10.1200\/JCO.1998.16.10.3426"},{"key":"18","unstructured":"18. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15: 3149-3155, 1997."},{"key":"#cr-split#-19.1","unstructured":"19. Aihara T, Toyama T, Takahashi M, et al. Nyugan Shinryo guideline 2015 nen-ban [Breast Cancer Clinical guideline 2015]. KANEHARA &amp"},{"key":"#cr-split#-19.2","unstructured":"Co., LTD., Tokyo, 2015: 199-204."},{"key":"20","unstructured":"20. Waks AG, Tolaney SM, Galar A, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 154: 359-367, 2015."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tolaney SM, Partridge AH, Sheib RG, et al. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 24: 5330-5331, 2006.","DOI":"10.1200\/JCO.2006.08.1083"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Khoo C, Gilchrist J, Williamson JP, et al. Pneumocystis jirovecii in a patient on dose-dense chemotherapy for early breast cancer. Respirol Case Rep 7: e00459, 2019.","DOI":"10.1002\/rcr2.459"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Watanabe H, Kitahara Y, Murakami Y, et al. Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med 59: 987-990, 2020.","DOI":"10.2169\/internalmedicine.3907-19"},{"key":"24","unstructured":"24. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21: 4165-4174, 2003."},{"key":"25","unstructured":"25. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17: 409-414, 2006."},{"key":"26","unstructured":"26. Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4: 348-353, 2003."},{"key":"27","unstructured":"27. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25-32, 2012."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663-1671, 2008.","DOI":"10.1056\/NEJMoa0707056"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.","DOI":"10.1056\/NEJMoa0910383"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/8\/60_5089-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T03:53:24Z","timestamp":1618631604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/8\/60_5089-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5089-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}